West Pharmaceutical Services Inc (WST)

Debt-to-equity ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 2,682,300 2,752,100 2,576,800 2,680,600 2,881,000 2,868,200 2,746,700 2,776,200 2,684,900 2,470,800 2,424,400 2,326,200 2,335,400 2,202,300 2,032,600 1,829,000 1,854,500 1,718,900 1,606,300 1,490,200
Debt-to-equity ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $2,682,300K
= 0.00

The debt-to-equity ratio for West Pharmaceutical Services Inc has remained at 0.00 consistently across all reported periods from March 31, 2020, to December 31, 2024. This ratio indicates that the company is not relying on debt financing to fund its operations, as its total debt is either extremely low or non-existent in relation to its shareholders' equity. A debt-to-equity ratio of 0.00 typically signifies a strong financial position, as there is no debt to be compared with the equity in the business. This may suggest that the company relies more on equity funding, which could imply lower financial risk and greater financial stability. However, it's important to note that while a low debt-to-equity ratio can be positive, it may also indicate missed opportunities to leverage debt for potential growth or investment purposes.


Peer comparison

Dec 31, 2024

Company name
Symbol
Debt-to-equity ratio
West Pharmaceutical Services Inc
WST
0.00
Carlisle Companies Incorporated
CSL
0.00